Article
Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.
The Journal of clinical investigation - 1 Feb 2007
Li Danan, Ji Hongbin, Zaghlul Sara, McNamara Kate, Liang Mei-Chih, Shimamura Takeshi, Kubo Shigeto, Takahashi Masaya, Chirieac Lucian R, Padera Robert F, Scott Andrew M, Jungbluth Achim A, Cavenee Webster K, Old Lloyd J, Demetri George D, Wong Kwok-Kin
Abstract excerpt
Activating EGFR mutations occur in human non-small cell lung cancer (NSCLC), with 5% of human lung squamous cell carcinomas having EGFRvIII mutations and approximately 10%-30% of lung adenocarcinomas having EGFR kinase domain mutations. An EGFR-targeting monoclonal antibody, mAb806, recognizes a conformational epitope of WT EGFR as well as the truncated EGFRvIII mutant. To explore the anticancer spectrum of this...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.